870221-49-1

Basic information

• Product Name: 4-(2-Chloropyridin-3-yl)pyrimidin-2-amine
• Synonyms: 4-(2-Chloropyridin-3-yl)pyrimidin-2-amine
• CAS NO: 870221-49-1
• Molecular Formula: C₉H₇ClN₄
• Molecular Weight: 206.63168
• Mol File: 870221-49-1.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(2-Chloropyridin-3-yl)pyrimidin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Chloropyridin-3-yl)pyrimidin-2-amine(870221-49-1)
• EPA Substance Registry System: 4-(2-Chloropyridin-3-yl)pyrimidin-2-amine(870221-49-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 870221-49-1(Hazardous Substances Data)

Upstream product

• 870221-50-4 (E)-1-(2-chloropyridin-3-yl)-3-(dimethylamino)-prop-2-en-1-one 
• 50-01-1 guanidine hydrochloride 

Downstream Products

• 870221-48-0 N-(4-(2-chloropyridin-3-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)benzamide 
• 945595-80-2 AMG 900 
• 945599-45-1 4-(2-(4-aminophenoxy)pyridin-3-yl)pyrimidin-2-amine 

Relevant articles and documents

N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

The present invention relates to methods of using the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine or a pharmaceutically acceptable salt thereof, to treat cancers, including solid tumors, which have become resistant to treatment with chemotherapeutic agents, including anti-mitotic agents such as taxanes, and/or other anti-cancer agents, including aurora kinase inhibiting agents. The invention also includes methods of treating cancers refractory to such treatments by administering a pharmaceutical composition, comprising the compound to a cancer subject.

Discovery of N -(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines

Efforts to improve upon the physical properties and metabolic stability of Aurora kinase inhibitor 14a revealed that potency against multidrug-resistant cell lines was compromised by increased polarity. Despite its high in vitro metabolic intrinsic cleara

Use of AMG 900 for the Treatment of Cancer

The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer.